{"entity":{"id":"nct06898970","kind":"trial","name":"Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma","aka":[],"tldr":"A phase 2 trial of Vusolimogene oderparepvec and Pembrolizumab in Angiosarcoma, run by Varun Monga, MBBS, now recruiting.","summary":"Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma is a phase 2 interventional study registered as NCT06898970 by Varun Monga, MBBS, with 18 participants planned, started 2026-01-09 and due to reach its primary completion in 2029-10-31. Interventions recorded: Vusolimogene Oderparepvec (VO), Pembrolizumab. Conditions recorded: Angiosarcoma, Angiosarcoma, Adult.\n\nLinked to the drug Vusolimogene oderparepvec because the registry names it among its interventions and Angiosarcoma among its conditions. Registry record only: no result has been read by an editor.","status":"recruiting","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT06898970","url":"https://clinicaltrials.gov/study/NCT06898970"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["angiosarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":["vusolimogene-oderparepvec","pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06898970","phase":"2","setting":"An Open-Label, Multicenter, Phase 2 Study With Safety Lead-In of Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab in Patients With Angiosarcoma","sponsor":"Varun Monga, MBBS","participation":[{"nct":"NCT06898970","source":"https://clinicaltrials.gov/study/NCT06898970","fetchedAt":"2026-10-07T16:55:17.578Z","studySha256":"df231559e74b138b9bbad5ebcac8d066388d8dffa0e68e40efa97714dee17b66","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-01","leadSponsor":"Varun Monga, MBBS","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":18,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["United States"]}],"started":"2026-01-09","startedType":"actual","enrolled":18,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06898970/","neighbours":{"cancer":[{"id":"angiosarcoma","kind":"cancer","name":"Angiosarcoma","route":"/cancers/angiosarcoma/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"vusolimogene-oderparepvec","kind":"drug","name":"Vusolimogene oderparepvec","route":"/drugs/vusolimogene-oderparepvec/"}]}}